Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: fixed dose combination therapies - Celator Pharmaceuticals

Drug Profile

Research programme: fixed dose combination therapies - Celator Pharmaceuticals

Alternative Names: AUY 922/docetaxel - Celator Pharma; CPX-571; Docetaxel/luminespib - Celator Pharma; Ipatasertib/selumetinib - Celator Pharma; Targeted cancer therapies: Celator Pharma

Latest Information Update: 27 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celator Pharmaceuticals
  • Developer Celator Pharmaceuticals; Jazz Pharmaceuticals Inc
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis modulators; DNA cross linking agents; DNA synthesis inhibitors; DNA topoisomerase I inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Histone acetyltransferase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors; Raf kinase inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer
  • No development reported Head and neck cancer; Lung cancer

Most Recent Events

  • 27 Dec 2022 Preclinical development is ongoing in Cancer in USA (unspecified)
  • 20 Feb 2020 Preclinical trials in Cancer in USA (Jazz Pharmaceuticals pipeline, February 2020)
  • 30 Jul 2019 Array Biopharma has been acquired by Pfizer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top